5.12
Phase-II-Reaktionen: Methylierungsreaktionen
Die Methylierung ist ein Biotransformationsprozess der Phase II, bei dem eine Methylgruppe an ein Substrat gebunden wird. Enzyme, die als Methyltransf…
Phase-II-Methylierungsreaktionen beinhalten die Bindung einer Methylgruppe an ein Substrat. Diese Reaktion ist die Umkehrung der Phase-I-Demethylierung. Es verfügt jedoch über einen Reaktionsmechanismus vom Typ Phase II.
Methyltransferasen wie die Catechol-O-Methyltransferase (COMT) und die Thiopurin-Methyltransferase (TPMT) katalysieren diese Reaktionen in erster Linie.
Die Methylierung umfasst einen zweistufigen Mechanismus: eine anfängliche Aktivierung des Coenzyms SAM, das eine Methylgruppe auf das Substrat überträgt, katalysiert durch eine Methyltransferase. SAB wird als Nebenprodukt freigesetzt.
Obwohl die methylierten Produkte keine höhere Polarität oder Wasserlöslichkeit als ihre Mutterarzneimittel aufweisen, weisen sie die gleiche oder eine verbesserte pharmakologische Aktivität auf.
Funktionelle Gruppen, die zur Methylierung fähig sind, umfassen Hydroxyl-, Amin-, Thiol- und Carbonsäuregruppen.
Morphin ist ein Beispiel für ein Medikament, das einer Methylierung unterzogen wird.
Die Methylierung ist auch eine wichtige Reaktion bei der Biosynthese und Inaktivierung von endogenen Aminen.
View the full transcript and gain access to JoVE Core videos
Q1: What is the two-step mechanism of methylation in phase II reactions?
Methylation involves two sequential steps. First, a methyltransferase enzyme catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, producing S-adenosylhomocysteine (SAH) as a byproduct. Second, SAH undergoes further metabolism into homocysteine, which can be recycled back to methionine through remethylation, completing the cycle.
Q2: Which enzymes catalyze methylation reactions and what substrates do they target?
Methyltransferases such as catechol-O-methyltransferase (COMT) and thiopurine methyltransferase (TPMT) catalyze methylation reactions. These enzymes target functional groups including hydroxyl, amine, thiol, and carboxylic acid groups on drug substrates. The methylation process modifies these groups to facilitate drug metabolism and elimination.
Q3: How does methylation differ from phase I demethylation reactions?
Methylation is essentially the reverse of phase I demethylation, involving the addition of a methyl group rather than its removal. However, methylation operates through a phase II-type reaction mechanism, making it a conjugation-style biotransformation. This distinction reflects methylation's role in drug inactivation and elimination despite its mechanistic similarity to phase I processes.
Q4: What are the pharmacological characteristics of methylated drug metabolites?
Methylated products typically exhibit altered pharmacological activity compared to parent drugs. While they generally show equal or enhanced activity in some cases, they often display decreased affinity for target receptors or enzymes. Notably, methylated metabolites are not necessarily more water-soluble than their parent drugs, distinguishing methylation from other phase II conjugation reactions.
Q5: How does codeine undergo methylation to produce morphine?
Codeine is methylated by methyltransferase enzymes, which transfer a methyl group from SAM to hydroxyl groups on the codeine molecule. This methylation converts codeine into morphine, a more potent analgesic. This transformation exemplifies how methylation can enhance a drug's pharmacological activity and demonstrates the clinical significance of phase II methylation reactions.
Q6: What role does methylation play in endogenous amine metabolism?
Methylation is a significant reaction in both the biosynthesis and inactivation of endogenous amines. For example, dopamine undergoes methylation to produce epinephrine, a hormone critical to the body's stress response. This demonstrates that methylation extends beyond drug metabolism to regulate important physiological processes involving neurotransmitters and hormones.
Q7: Why is methylation considered a phase II biotransformation despite reversing phase I demethylation?
Although methylation reverses phase I demethylation mechanistically, it employs a phase II-type reaction mechanism characteristic of conjugation reactions. Methylation uses a coenzyme (SAM) and produces a byproduct (SAH), similar to other phase II processes. This classification reflects methylation's role in drug detoxification and elimination, transforming lipophilic drugs into metabolites for excretion.